ISDA

Deposition Date 2012-06-20

Release Date 2012-07-11

Last Version Date 2024-02-28

Entry Detail

PDB ID:

4FOD

Keywords:

Transferase/Inhibitor

Title:

Crystal structure of human anaplastic lymphoma kinase in complex with acyliminobenzimidazole inhibitor 36

Biological Source:

Source Organism:

Homo sapiens (Taxon ID: 9606)

Host Organism:

Spodoptera frugiperda

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

2.00 Å

R-Value Free:

0.22

R-Value Work:

0.17

R-Value Observed:

0.17

Space Group:

P 21 21 21

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Molecule:ALK tyrosine kinase receptor
Gene (Uniprot):ALK
Mutations:C1097S
Chain IDs:A
Chain Length:333
Number of Molecules:1
Biological Source:Homo sapiens

UniProt ID:Q9UM73 Pfam ID:PF07714 EC:2.7.10.1

Ligand Molecules

0UV

GOL

Primary Citation

The Discovery and Optimization of a Novel Class of Potent, Selective, and Orally Bioavailable Anaplastic Lymphoma Kinase (ALK) Inhibitors with Potential Utility for the Treatment of Cancer.

Lewis, R.T, Bode, C.M, Choquette, D.M, Potashman, M, Romero, K, Stellwagen, J.C, Teffera, Y, Moore, E, Whittington, D.A, Chen, H, Epstein, L.F, Emkey, R, Andrews, P.S, Yu, V.L, Saffran, D.C, Xu, M, Drew, A, Merkel, P, Szilvassy, S, Brake, R.L.Show

J.Med.Chem. 55 6523 6540 (2012)

PMID: 22734674 DOI: 10.1021/jm3005866

Abstact

A class of 2-acyliminobenzimidazoles has been developed as potent and selective inhibitors of anaplastic lymphoma kinase (ALK). Structure based design facilitated the rapid development of structure-activity relationships (SAR) and the optimization of kinase selectivity. Introduction of an optimally placed polar substituent was key to solving issues of metabolic stability and led to the development of potent, selective, orally bioavailable ALK inhibitors. Compound 49 achieved substantial tumor regression in an NPM-ALK driven murine tumor xenograft model when dosed qd. Compounds 36 and 49 show favorable potency and PK characteristics in preclinical species indicative of suitability for further development.

Legend

Protein

Chemical

Disease

Primary Citation of related structures